UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 21, 2018

 

ADVAXIS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-36138   02-0563870

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

305 College Road East

Princeton, New Jersey, 08540

(Address of Principal Executive Offices)

 

(609) 452-9813

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act.
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
[  ] Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[  ]

 

 

 

     

 

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On March 21, 2018, at the 2018 annual meeting (the “Annual Meeting”) of stockholders of Advaxis, Inc. (the “Company” or “Advaxis”), the stockholders approved an increase of authorized shares of common stock by 30,000,000 from the previously-authorized 65,000,000, bringing the total number of authorized shares of common stock to 95,000,000 shares (the “Amendment”).

 

This Amendment is described in the Company’s proxy statement and annual report to stockholders for the year ended October 31, 2017, filed with the Securities and Exchange Commission on February 6, 2018 (the “Proxy Statement”). This description of the Amendment is qualified in its entirety by reference to the text of the Amendment to the Company’s Amended and Restated Certificate of Incorporation, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Amendment became effective upon filing of the Amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on March 21, 2018.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

The following matters were voted on by the stockholders at the Annual Meeting: the election of directors, the approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the Company’s authorized share capital by 30,000,000 shares of common stock, the approval of the Company’s 2018 Employee Stock Purchase Plan, and the ratification of the appointment of Marcum LLP as Advaxis’ independent registered public accounting firm for the fiscal year ending October 31, 2018. At the meeting, Dr. David Sidransky, Dr. James P. Patton, Roni A. Appel, Richard J. Berman, and Dr. Samir N. Khleif were re-elected to the Board.

 

Proposal 1

 

The vote with respect to each nominee is set forth below:

 

Nominee   Total Votes For     Total Votes Withheld     Broker Non-Votes  
Dr. David Sidransky     11,947,489       4,707,635       16,866,459  
Dr. James P. Patton     11,460,967       5,194,157       16,866,459  
Roni A. Appel     12,706,506       3,948,618       16,866,459  
Richard J. Berman     12,825,177       3,829,947       16,866,459  
Dr. Samir Khleif     12,269,918       4,385,206       16,866,459  

 

     

 

 

Proposal 2

 

The vote with respect to the approval of an amendment to Advaxis’ Amended and Restated Certificate of Incorporation is set forth below:

 

Total Votes For     Total Votes Against     Abstentions     Broker Non-Votes  
  25,040,407       8,140,730       340,446       0  

 

Proposal 3

 

The vote with respect to the approval of Advaxis’ 2018 Employee Stock Purchase Plan is set forth below:

 

Total Votes For     Total Votes Against     Abstentions     Broker Non-Votes  
  13,161,780       3,384,560       108,784       16,866,459  

 

Proposal 4

 

The vote with respect to the ratification of the appointment of Marcum LLP as Advaxis’ independent registered public accounting firm for the fiscal year ending October 31, 2018, is set forth below:

 

Total Votes For     Total Votes Against     Abstentions     Broker Non-Votes  
  29,615,336       3,156,631       749,616       0  

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are furnished as part of this report:

 

Exhibit
Number

 

Description

     
3.1   Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc.

 

     

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ADVAXIS, INC.
  (Registrant)
     
  By /s/ Sara M. Bonstein
    Sara M. Bonstein
    Executive Vice President and Chief Financial Officer

 

Date: March 21, 2018

 

     

 

 

Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ayala Pharmaceuticals (QX) Charts.
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ayala Pharmaceuticals (QX) Charts.